Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213).

Suppr

超能文献

作者信息

Creaven P J, Newman S J, Selawry O S, Cohen M H, Primack A

出版信息

Cancer Chemother Rep. 1974 Nov-Dec;58(6):901-7.

PMID:4615787

Abstract

摘要

相似文献

Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213).

Cancer Chemother Rep. 1974 Nov-Dec;58(6):901-7.

4'-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) and 4'-demethylepipodophyllotoxin 9-(4.6-0-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213) in childhood cancer: preliminary observations.

Cancer Chemother Rep. 1975 Jul-Aug;59(4):743-9.

Clinical study of the new podophyllotoxin derivative, 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene- beta-D-glucopyranoside) (NSC-141540; VP-16-213), in solid tumors.

Cancer Chemother Rep. 1975 Jul-Aug;59(4):737-42.

Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).

Cancer Chemother Rep. 1972 Dec;56(6):769-77.

Phase I clinical trial of a single-dose and two weekly schedules of ICRF-159 (NSC-129943).

Cancer Chemother Rep. 1974 May-Jun;58(3):393-400.

Experience with 4'-demethylepipodo-phyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside); VM-26; NSC-122819 in the treatment of malignant lymphosis.

Eur J Cancer (1965). 1974 Feb;10(2):93-8. doi: 10.1016/0014-2964(74)90058-9.

Comparative cytotoxic and cytokinetic effects of the epipodophyllotoxins 4'-demethylepipodophyllotoxin-9-(4,6-O-2-ethylidene-beta-D-glucopyranoside) and 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) and their metabolites on human leukemic lymphoblasts.

Cancer Res. 1983 Dec;43(12 Pt 1):5699-706.

A clinical trial of the oral form of 4'-demethyl-epipodophyllotoxin-beta-D ethylidene glucoside (NSC 141540) VP 16-213.

Cancer. 1975 Apr;35(4):1141-4. doi: 10.1002/1097-0142(197504)35:4<1141::aid-cncr2820350418>3.0.co;2-3.

Clinical evaluation of hexamethylmelamine (NSC-13875).

Cancer Chemother Rep. 1973 Feb;57(1):51-8.

Adriamycin (NSC-123127) in combination with cyclophosphamide (NSC-26271): a phase I and II evaluation.

Cancer Chemother Rep. 1974 Nov-Dec;58(6):919-26.

引用本文的文献

Current development of podophyllotoxins.

Cancer Chemother Pharmacol. 1982;7(2-3):93-8. doi: 10.1007/BF00254528.

VP16-213 (etoposide). A critical review of its activity.

Cancer Chemother Pharmacol. 1982;7(2-3):81-5. doi: 10.1007/BF00254526.

The podophyllotoxin derivatives VP16-213 and VM26.

Cancer Chemother Pharmacol. 1982;7(2-3):73-80. doi: 10.1007/BF00254525.

The clinical pharmacology of VM26 and VP16-213. A brief overview.

Cancer Chemother Pharmacol. 1982;7(2-3):133-40. doi: 10.1007/BF00254535.

[Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].

Klin Wochenschr. 1981 Nov 2;59(21):1177-88. doi: 10.1007/BF01721212.

Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer.

Cancer Chemother Pharmacol. 1984;12(1):64-5. doi: 10.1007/BF00255913.

The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung.

Cancer Chemother Pharmacol. 1987;19(1):16-20. doi: 10.1007/BF00296248.

Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies.

Cancer Chemother Pharmacol. 1987;19(3):250-2. doi: 10.1007/BF00252981.

Podophyllotoxin derivative VP 16-213.

Cancer Chemother Pharmacol. 1979;3(2):71-80. doi: 10.1007/BF00254976.

Antineoplastic drugs: clinical pharmacology and therapeutic use.

Drugs. 1978 Jul;16(1):46-87. doi: 10.2165/00003495-197816010-00003.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验